Creating a Global Research Database That Connects Genetic Information and Long-term Health Data to Improve Personalized Treatment for People With Serious Mental Illness

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-110
SponsorAkrivia Health

About this trial

This observational study aims to provide new insights into the nature and classification of severe mental illness and dementias that in time should help improve diagnostic practise, and enable the development of new and improved treatments. The investigators will achieve aims by gathering information and biological samples from over 50,000 research participants and then linking this information with participants' electronic health records, genetic and other potential markers of mental illnesses (called biomarkers, derived from biological samples). The investigators will use this resource to analyse how potential risk factors - genetic, other biological and non-biological (related to the participants' life circumstances) - influence participants' experiences, symptoms, and outcomes (both mental and physical health). The investigators will also use advanced analysis to assess whether there may be better ways of grouping together and understanding the experiences of those with severe mental illnesses and dementias. Given the value and importance of this resource for advancing mental health research, the investigators will also make the data available to other researchers to pursue these broad research aims.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

None

Disqualifiers

None

Trial population

Participants aged 18 and over with neuropsychiatric (MDD, BD or Schizophrenia) or Neurodegenerative disorder (dementia).

Trial design

Design model

Cohort

Time perspective

Cross-sectional

Treatments tested in this trial

  • Not applicable- observational study

    Other intervention

    This is non-interventional, cross-sectional observational study and thus there is no intervention.

Treatment groups

50,000 Participants
are divided into 3 treatment groups
Group A: Cohort 11 intervention
Group B: Cohort 21 intervention
Group C: Cohort 31 intervention

Trial outcomes

Primary outcomes

1

Diagnosis of participants with schizophrenia, bipolar disorder or schizoaffective disorder

The primary outcome measure of this study is the diagnosis of participants with bipolar disorder, schizophrenia or schizoaffective disorder in accordance with ICD-10 criteria

Time frame
1 month from sample collection and baseline assessment.

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Akrivia Health

Lead sponsor

Cardiff University

Collaborator